ULTrasound Accelerated ThrombolysIs of PulMonAry Embolism — ULTIMA

Submassive Pulmonary Embolism Clinical Trial

Official title:
Randomized, Controlled Study Comparing EKOS EkoSonic Ultrasound Accelerated Thrombolysis to Anticoagulation in the Treatment of Sub-massive Pulmonary Embolism

Status Completed

Clinical Trial Summary

The ULTIMA study is intended to prove that in patients with pulmonary embolism and a right ventricular end diastolic diameter to left ventricular end diastolic diameter ratio ≥1 (RV/LV ratio) will benefit from treatment with ultrasound accelerated thrombolysis (rt-PA) as compared to unfractionated heparin anticoagulation. Specifically, at 24 hours the RV/LV ratio will be significantly reduced in the treatment arm compared to the control arm.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01166997
Study type	Interventional
Source	Boston Scientific Corporation
Contact
Status	Completed
Phase	Phase 3
Start date	July 2010
Completion date	May 2013

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00191724` - Adjuvant Treatment of Pulmonary Embolism With Drotrecogin Alfa (Activated): Phase II Exploratory Study	Phase 2
Completed	`NCT01899339` - Long Term Effects of Treating Submassive Pulmonary Embolism With Ultra-sound Accelerated Thrombolysis
Completed	`NCT03389971` - ULTRAsound-assisted Catheter vs. STAndaRd Catheter Thrombolysis for Submassive Pulmonary Embolism	N/A
Completed	`NCT02692586` - FlowTriever Pulmonary Embolectomy Clinical Study	N/A